Author:
Neubauer A.,Knigge O.,Zimmermann R.,Krahl D.,Schmidt C. A.,Oertel J.,Huhn D.
Publisher
Springer Berlin Heidelberg
Reference18 articles.
1. Atzpodien J, Körfer A, Franks CR, Poliwoda H and Kirchner H (1990) Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies. Lancet 1: 1509–1512
2. Berman E, Heller G, Santorsa J, McKenzie S, Gee T, Kempin S, Gulati S, Andreeff M, Kolitz J, Gabrilove J, et al. (1991) Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Blood 77: 1666–1674
3. Brunda MJ, Tarnowski D and Davatelis V (1986) Interaction of recombinant interferons with recombinant interleukin-2: Differential effects on natural killer cell activity and interleukin-2 activated killer cells. Int. J. Cancer. 37: 787–793
4. Buchner T, Hiddemann W, Wormann B, Loffler H, Maschmeyer G, Hossfeld D, Ludwig WD, Nowrousian M, Aul C, Schaefer UW, et al. (1992) Longterm effects of prolonged maintenance and of very early intensification chemotherapy in AML: data from AMLCG. Leukemia 6 Suppl 2: 68–71
5. Buechner T and Hiddemann W (1990) Treatment strategies in acute myeloid leukemia (AML). Blut 60: 61–67